Abstract
Background
Triple negative breast cancer (TNBC) is a poor prognosis breast cancer with the highest mutation rate and limited treatment options. MiR-155 is highly expressed in TNBC, but its role and potential mechanism in TNBC remain to be elucidated.
Objective
The aim of this study is to examine the effect of interfering with miRNA-155 on the inflammatory pathway of NLRP 3 in TNBC (MDA-MB-231).
Methods
MiRNA-155-specific interference (Si-miR-155) on MDA-MB-231 cell was manifested by transfection of miRNA-155 inhibitor. Meanwhile, blank control (Blank) and negative control (NC) were set. Cell growth and proliferation rate were detected by MTT; apoptosis rate were detected by flow cytometry; colony forming test was used to detected cell viability; cell migration ability was detected by Wound healing assay; TNF-α, IL-18, IL-6 and IL-1β levels were detected by ELISA. The mRNA of miRNA-155, NLRP3, ASC, caspase-1 and Ki67 were detected by qRT-PCR. The expression levels of NLRP3, caspase-1, ASC and Ki67 were detected by Western blotting.
Results
The proliferation rate of Si-miRNA-155 group decreased, while the apoptosis rate increased significantly. After interfering with miRNA-155, the number of cancer cell colonies and the migration ability was decreased, and the secretion levels of IL-18, TNF-α, IL-6 and IL-1β were also inhibited. Moreover the mRNA and protein expression of NLRP3, caspase-1, ASC and Ki67 were significantly suppressed.
Conclusions
Interference with miRNA-155 can inhibit the NLRP3 pathway of MDA-MB-231 cells, as well as the proliferation, migration and inflammatory factor secretion of MDA-MB-231 cell, and can accelerate its apoptosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA (2015) Subtyping of triple-negative breast cancer: implications for therapy. Cancer 121:8–16. https://doi.org/10.1002/cncr.28914
Baldwin AG, Tapia VS, Swanton T, White CS, Beswick JA, Brough D, Freeman S (2018) Design, synthesis and evaluation of oxazaborine inhibitors of the NLRP3 inflammasome. Chem Med Chem 13:312–320. https://doi.org/10.1002/cmdc.201700731
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13:674–690. https://doi.org/10.1038/nrclinonc.2016.66
Broz P, Newton K, Lamkanfi M, Mariathasan S, Dixit VM, Monack DM (2010) Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J Exp Med 207:1745–1755. https://doi.org/10.1084/jem.20100257
Camorani S, Fedele M, Zannetti A, Cerchia L (2018) TNBC challenge: oligonucleotide aptamers for new imaging and therapy modalities. Pharmaceuticals (Basel). https://doi.org/10.3390/ph11040123
Chen S, Smith BA, Iype J, Prestipino A, Pfeifer D, Grundmann S, Schmitt-Graeff A, Idzko M, Beck Y, Prinz G et al (2015) MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation. Blood 126:103–112. https://doi.org/10.1182/blood-2014-12-617258
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434. https://doi.org/10.1158/1078-0432.Ccr-06-3045
Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES (2009) AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458:509–513. https://doi.org/10.1038/nature07710
He Y, Hara H, Núñez G (2016) Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci 41:1012–1021. https://doi.org/10.1016/j.tibs.2016.09.002
Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA (2009) AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458:514–518. https://doi.org/10.1038/nature07725
Hu Q, Zhao F, Guo F, Wang C, Fu Z (2017) Polymeric nanoparticles induce NLRP3 inflammasome activation and promote breast cancer metastasis. Macromol Biosci. https://doi.org/10.1002/mabi.201700273
Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121:2373–2380. https://doi.org/10.1002/ijc.23173
Jang MH, Kim HJ, Gwak JM, Chung YR, Park SY (2017) Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer. Hum Pathol 68:69–78. https://doi.org/10.1016/j.humpath.2017.08.026
Kanneganti TD, Lamkanfi M, Núñez G (2007) Intracellular NOD-like receptors in host defense and disease. Immunity 27:549–559. https://doi.org/10.1016/j.immuni.2007.10.002
Kantono M, Guo B (2017) Inflammasomes and cancer: the dynamic role of the inflammasome in tumor development. Front Immunol 8:1132. https://doi.org/10.3389/fimmu.2017.01132
Karki R, Man SM, Kanneganti TD (2017) Inflammasomes and cancer. Cancer Immunol Res 5:94–99. https://doi.org/10.1158/2326-6066.Cir-16-0269
Kia V, Paryan M, Mortazavi Y, Biglari A, Mohammadi-Yeganeh S (2019) Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells. J Cell Biochem 120:5666–5676. https://doi.org/10.1002/jcb.27850
Kim S, Lee E, Jung J, Lee JW, Kim HJ, Kim J, Yoo HJ, Lee HJ, Chae SY, Jeon SM et al (2018) microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer. Oncogene 37:2982–2991. https://doi.org/10.1038/s41388-018-0124-4
Komada T, Muruve DA (2019) The role of inflammasomes in kidney disease. Nat Rev Nephrol 15:501–520. https://doi.org/10.1038/s41581-019-0158-z
Liu R, Chen H, Zhao P, Chen CH, Liang H, Yang C, Zhou Z, Zhi X, Liu S, Chen C (2020) Mifepristone derivative FZU-00,003 suppresses triple-negative breast cancer cell growth partially via miR-153-KLF5 axis. Int J Biol Sci 16:611–619. https://doi.org/10.7150/ijbs.39491
Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426. https://doi.org/10.1016/s1097-2765(02)00599-3
Song X, Liu Z, Yu Z (2019) LncRNA NEF is downregulated in triple negative breast cancer and correlated with poor prognosis. Acta Biochim Biophys Sin (Shanghai) 51:386–392. https://doi.org/10.1093/abbs/gmz021
Waldner MJ, Neurath MF (2009) Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 31:249–256. https://doi.org/10.1007/s00281-009-0161-8
Wang X, Yi F (2015) Implication of pattern-recognition receptors in cardiovascular diseases. Antioxid Redox Signal 22:1130–1145. https://doi.org/10.1089/ars.2014.6184
Wang T, Meng J, Wang C, Wen T, Jia M, Ge Y, Xie L, Hao S, Liu J, Xu H (2019) Inhibition of murine breast cancer metastases by hydrophilic As(4)S(4) nanoparticles is associated with decreased ROS and HIF-1α downregulation. Front Oncol 9:333. https://doi.org/10.3389/fonc.2019.00333
Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, Corbalán-Campos J, Hartmann P, Thiemann A, Weber C, Schober A (2013) The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation 127:1609–1619. https://doi.org/10.1161/circulationaha.112.000736
Wu X, Dong L, Lin X, Li J (2017) Relevance of the NLRP3 inflammasome in the pathogenesis of chronic liver disease. Front Immunol 8:1728. https://doi.org/10.3389/fimmu.2017.01728
Xu H, Yang J, Gao W, Li L, Li P, Zhang L, Gong YN, Peng X, Xi JJ, Chen S et al (2014) Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513:237–241. https://doi.org/10.1038/nature13449
Yang LW, Wu XJ, Liang Y, Ye GQ, Che YC, Wu XZ, Zhu XJ, Fan HL, Fan XP, Xu JF (2020) miR-155 increases stemness and decitabine resistance in triple-negative breast cancer cells by inhibiting TSPAN5. Mol Carcinog 59:447–461. https://doi.org/10.1002/mc.23167
Zhang L, Li H, Zang Y, Wang F (2019) NLRP3 inflammasome inactivation driven by miR-223-3p reduces tumor growth and increases anticancer immunity in breast cancer. Mol Med Rep 19:2180–2188. https://doi.org/10.3892/mmr.2019.9889
Zhao Y, Guo Q, Zhao K, Zhou Y, Li W, Pan C, Qiang L, Li Z, Lu N (2017) Small molecule GL-V9 protects against colitis-associated colorectal cancer by limiting NLRP3 inflammasome through autophagy. Oncoimmunology 7:e1375640. https://doi.org/10.1080/2162402x.2017.1375640
Acknowledgement
We thank Guangzhou Yujia Biotechnology Co., Ltd. for conducting some experiments in their laboratory.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Yangying Hu, Deqi Wu, Xiangjun Feng and Zhijie Shi declare that they have no conflict of interest.
Ethical approval
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hu, Y., Wu, D., Feng, X. et al. Research on the effect of interfering with miRNA-155 on triple-negative breast cancer cells. Genes Genom 44, 1117–1124 (2022). https://doi.org/10.1007/s13258-021-01106-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13258-021-01106-y